Oh, it seems I misread your comments on the scathing report on Marie’s over generous pay and the company’s poor performance as being supportive of the company, yet the opposite is the case. Sorry soud; good to see we’re on the same page of disquiet on this.
As you’s said, we all want the company to succeed. It’s long past time for the CEO and her friendly Board to heed shareholders concerns on the range of significant issues raised here over and over and over.
Not the least the complaints about inadequate information from the company including the lack of transparency on US sales, the number of Australian pharmacies on the Evolis books, their sales and turn-around guidance, the Board’s position on the escalating prospect of a low ball takeover offer or management buy-out, a Board announcement (as is usual from ASX stocks in similar circumstances) on the sp collapse and destruction of shareholder wealth and a clearer statement on the Board’s plans or alternatives for its Midkine portfolio.
Yet shareholders concerns and pleas have been ignored time after time after time with the silence of the incumbents instead shamefully leaving any response and push-back against our disquiet up to their lead disciples T7 and Leverage.
CDY Price at posting:
22.0¢ Sentiment: Hold Disclosure: Held